Astellas Announces 32 Percent Earnings Increase For Fiscal 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Tokyo firm anticipates 10.4 percent drop in fiscal 2008 with Prograf patent expiry.
You may also be interested in...
Astellas Tacrolimus Approval Remains At Bay
On heels of second “approvable” letter for kidney transplant rejection, FDA issues another approvable for liver indication.
Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis
$760 million gets Japanese pharma a Phase I compound and research into more potential disease modifying therapies for Alzheimer’s.
FDA Clears Astellas’ Lexiscan For Market
Bigger sales force backs soon-to-launch imaging agent.